Last reviewed · How we verify
Tadalafil versus tamsulosin as MET
Tadalafil versus tamsulosin as MET is a PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin) Small molecule drug developed by Beni-Suef University. It is currently FDA-approved for Benign prostatic hyperplasia with lower urinary tract symptoms, Erectile dysfunction (tadalafil).
Tadalafil is a phosphodiesterase-5 inhibitor that relaxes smooth muscle in the prostate and bladder, improving urinary flow; tamsulosin is an alpha-1A adrenergic antagonist that selectively blocks receptors in the prostate to reduce urinary obstruction.
Tadalafil is a phosphodiesterase-5 inhibitor that relaxes smooth muscle in the prostate and bladder, improving urinary flow; tamsulosin is an alpha-1A adrenergic antagonist that selectively blocks receptors in the prostate to reduce urinary obstruction. Used for Benign prostatic hyperplasia with lower urinary tract symptoms, Erectile dysfunction (tadalafil).
At a glance
| Generic name | Tadalafil versus tamsulosin as MET |
|---|---|
| Sponsor | Beni-Suef University |
| Drug class | PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin) |
| Target | PDE5 (tadalafil) vs. alpha-1A adrenergic receptor (tamsulosin) |
| Modality | Small molecule |
| Therapeutic area | Urology / Benign Prostatic Hyperplasia |
| Phase | FDA-approved |
Mechanism of action
This appears to be a comparative study (versus) rather than a single drug entity. Tadalafil works by inhibiting PDE5, increasing cGMP levels and promoting smooth muscle relaxation in lower urinary tract tissues. Tamsulosin selectively antagonizes alpha-1A receptors on prostatic smooth muscle, reducing dynamic obstruction. Both are used for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) but through distinct mechanisms.
Approved indications
- Benign prostatic hyperplasia with lower urinary tract symptoms
- Erectile dysfunction (tadalafil)
Common side effects
- Headache
- Dyspepsia
- Back pain
- Dizziness
- Orthostatic hypotension
- Retrograde ejaculation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tadalafil versus tamsulosin as MET CI brief — competitive landscape report
- Tadalafil versus tamsulosin as MET updates RSS · CI watch RSS
- Beni-Suef University portfolio CI
Frequently asked questions about Tadalafil versus tamsulosin as MET
What is Tadalafil versus tamsulosin as MET?
How does Tadalafil versus tamsulosin as MET work?
What is Tadalafil versus tamsulosin as MET used for?
Who makes Tadalafil versus tamsulosin as MET?
What drug class is Tadalafil versus tamsulosin as MET in?
What development phase is Tadalafil versus tamsulosin as MET in?
What are the side effects of Tadalafil versus tamsulosin as MET?
What does Tadalafil versus tamsulosin as MET target?
Related
- Drug class: All PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin) drugs
- Target: All drugs targeting PDE5 (tadalafil) vs. alpha-1A adrenergic receptor (tamsulosin)
- Manufacturer: Beni-Suef University — full pipeline
- Therapeutic area: All drugs in Urology / Benign Prostatic Hyperplasia
- Indication: Drugs for Benign prostatic hyperplasia with lower urinary tract symptoms
- Indication: Drugs for Erectile dysfunction (tadalafil)
- Compare: Tadalafil versus tamsulosin as MET vs similar drugs
- Pricing: Tadalafil versus tamsulosin as MET cost, discount & access